TetraLogic Pharmaceuticals Announces Publication of Structural Characterization of Birinapant
April 09 2014 - 6:30AM
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today
announced that data published in a forthcoming issue of the Journal
of Medicinal Chemistry of the American Chemical Society describes
the discovery and unique chemical features of its lead Smac-mimetic
birinapant, which is currently being tested in Phase 1 and Phase 2
clinical trials for hematological malignancies and solid tumors.
The publication entitled "Birinapant – A Smac-mimetic with
Improved Tolerability for the Treatment of Solid Tumors and
Hematological Malignancies" by Condon et al., will appear in the
May edition of Journal of Medicinal Chemistry.
It is available on-line at:
http://pubs.acs.org/doi/abs/10.1021/jm500176w
The paper reports details of 10 compounds from TetraLogic's
library of IAP-inhibitor compounds, and describes the differential
properties of monovalent IAP-inhibitors versus bivalent
Smac-mimetics. It further outlines the differences between the
first-generation and second-generation bivalent molecules such as
birinapant.
"We are delighted that this work is now published, as it
describes, at the structural level, the characteristics of bivalent
Smac-mimetics, and birinapant in particular and is the result of a
long-standing and very fruitful collaboration between TetraLogic
scientists and an outstanding group of collaborators." said C.
Glenn Begley, Chief Scientific Officer of TetraLogic. "These
data underpin our belief in birinapant's unique safety and efficacy
profile."
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics in
oncology and infectious diseases. Birinapant is currently
being tested in Phase 1 and Phase 2 clinical trials for
hematological malignancies and solid tumors. TetraLogic
recently announced an agreement to acquire SHAPE, a small molecule
that is entering Phase 2 trials for early-stage CTCL.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future
events or TetraLogic's pre-clinical and clinical development of
birinapant, SHAPE and other clinical programs, future expectations,
plans and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
the heading "Risk Factors" in our Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 19,2014.
Any forward-looking statements contained in this release speak only
as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT: Company Contact:
Pete A. Meyers
Chief Financial Officer and Treasurer
TetraLogic Pharmaceuticals Corporation
(610) 889-9900, x103
pete.meyers@tlog.com
Investor Relations Contact:
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024